Certifications, awards and grants

Two grants under the INVESTIGO program, part of the Recovery, Transformation, and Resilience Plan – Funded by the European Union – NextGenerationEU, for the hiring of young people (under 30 years old) seeking employment for the development and execution of research and innovation functions, tasks, and initiatives, granted by AGAUR (2023).

With the CARDIOSCOPE project (2022): Comprehensive and personalized assessment of acute coronary syndrome through a multi-omic approach and artificial intelligence strategy (2022).

To implement multi-omic approaches in the prevention and research of atherosclerotic cardiovascular diseases (2022).

(Generation of vascular risk assessment algorithms based on multi-omic techniques) from the joint ISCIII-CDTI 2023 call (“MISSION HEALTH 2023 PROJECTS”, EXP 00162694 / IDI-20230952).

Obtaining a grant under the 2022 public-private collaboration projects call financed by the Ministry of Science and Innovation and the State Research Agency. Project HARMONi – HARnessing the power of MultiOmics: towards the generation of Novel & Innovative diagnostic tools to improve cardiovascular risk prediction (CPP2022-010039).

Funded projects:

2021: Development of a diagnostic test for colorectal cancer based on metabolomics by Nuclear Magnetic Resonance.

2020: Diagnostic metabolomics, uncovering the molecular fingerprint of cardio-metabolic disease

2016: Design and automation of a lipidomic analysis by 1H-NMR for the estimation of cardiometabolic risk.

2014:Design and development of an in vitro diagnostic test for improved cardiovascular risk assessment.

India Bilateral Call –  Companion diagnostic for Sarogrlitazar, advancing cardiometabolic health: metabolomics for machine learning-based diagnostics.

Biosfer Teslab participates as CO-IP together with Dr. Xavier Correig, head of the metabolomics platform of the Instituto de Investigación Sanitaria Pere Virgili IISPV.
Project – VISIONING: covid-19 prognosis tool, an affordable metabolomic artificial Intelligence-assisted blood testing analysis.

“Biosfer Teslab has been a beneficiary of the European Regional Development Fund whose objective is to improve the use and quality of information and communication technologies and access to them and thanks to which it has implemented a communication strategy for the company for commercial purposes, to improve economic and social growth, to increase the positive perception among its current and future collaborators. January 2021. For this, it has had the support of the digital Xpande of the Reus Chamber of Commerce.”
A way to make Europe

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 822273.

BIOSFER TESLAB, SL supported by CDTI under the PID Programme is implementing the Development of a prediction test for cardiometabolic disease, based on the advanced molecular profile using Nuclear Magnetic Resonance (NMR) spectroscopy and machine learnig techniques.

BIOSFER TESLAB, SL supported by CDTI under the NEOTEC Operational Programme is implementing the Development of new in vitro test based on Nuclear Magnetic Resonance (NMR) spectroscopy for an early detection of cardiometabolic diseases and cardiovascular diseases.

Funded project: 1H-NMR glycoprotein analysis. An Advanced approach for inflammatory diseases diagnosis.

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

Enisa is a public company – dependent to the Ministry of  Industry, Energy and Tourism, via the General Directorate of Industries and small and medium-sized enterprises – that, since 1982,  is also actively involved in the financing of innovative and viable business projects.